Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Tetsuya Oguri"'
Autor:
Takahiro Hatta, Tetsunari Hase, Toru Hara, Tomoki Kimura, Eiji Kojima, Takashi Abe, Yoshitsugu Horio, Yasuhiro Goto, Naoya Ozawa, Naoyuki Yogo, Hirofumi Shibata, Tomoya Shimokata, Tetsuya Oguri, Masashi Yamamoto, Kiyoshi Yanagisawa, Masahiko Ando, Yuichi Ando, Masashi Kondo, Makoto Ishii, Yoshinori Hasegawa
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 15955-15969 (2023)
Abstract Background The Cockcroft–Gault formula is commonly used as a substitute for glomerular filtration rate (GFR) in Calvert's formula for carboplatin dosing, where adjusting serum creatinine measured using the enzymatic method with 0.2 mg/dL h
Externí odkaz:
https://doaj.org/article/a40d3403fb414a989bb00b6f8030a3d5
Autor:
Minoru, Horiuchi, Tetsuya, Oguri, Yusuke, Kagawa, Kazuki, Sone, Satoshi, Fukuda, Takehiro, Uemura, Osamu, Takakuwa, Ken, Maeno, Kennsuke, Fukumitsu, Yoshihiro, Kanemitsu, Tomoko, Tajiri, Hirotsugu, Ohkubo, Masaya, Takemura, Yutaka, Ito, Akio, Niimi
Publikováno v:
Anticancer Research. 42:1073-1079
The optimal chemotherapy for concurrent chemoradiotherapy (cCRT) of lung cancer is still unclear.We investigated the therapeutic effect of different chemotherapy regimens for cCRT of lung cancer in 65 patients at our hospital.Of the 65 patients, 53 w
Autor:
Akira, Takeuchi, Tetsuya, Oguri, Satoshi, Fukuda, Kazuki, Sone, Yusuke, Kagawa, Takehiro, Uemura, Osamu, Takakuwa, Ken, Maeno, Kensuke, Fukumitsu, Yoshihiro, Kanemitsu, Tomoko, Tajiri, Hirotsugu, Ohkubo, Masaya, Takemura, Yutaka, Ito, Akio, Niimi
Publikováno v:
Anticancer research. 40(8)
Organic cation transporter 6 (OCT6) encoded by solute carrier family 22 member 16 (SLC22A16) is involved in regulating cellular sensitivity and resistance to platinum derivatives. SLC22A16 has functional genetic variants but the association between t
Autor:
Yoichi Nakanishi, Satoshi Morita, Haruko Daga, Ryo Toyozawa, Takuma Yokoyama, Yasuo Iwamoto, Kazuhiko Nakagawa, Satoru Miura, Kaoru Tanaka, Hiroshige Yoshioka, Katsuya Hirano, Tetsuya Oguri, Atsushi Nakamura, Masahiko Ando, Motoko Tachihara, Ryo Ko, Akihiro Bessho, Isamu Okamoto, Nobuyuki Yamamoto, Takashi Ishiguro
Publikováno v:
CancerReferences. 126(16)
Background A randomized phase 3 study was performed to investigate the efficacy and safety of maintenance therapy with S-1 after induction therapy with carboplatin plus S-1 in patients with advanced squamous non-small cell lung cancer (NSCLC). Method
Autor:
Tomohiko Ogasawara, Takashi Abe, Tomoki Kimura, Yoshitsugu Horio, Tetsunari Hase, Yasuteru Sugino, Hiroshi Saito, Yoshinori Hasegawa, Kazuyoshi Imaizumi, Eiji Kojima, Tetsuya Oguri, Masahiro Nakatochi, Hideo Saka, Masahiko Ando, Kiyoshi Yanagisawa, Masashi Kondo, Asuki Fukatsu, Masashi Yamamoto, Masahiro Morise, Takashi Takahashi
Publikováno v:
Journal of Clinical Oncology. 38:9524-9524
9524 Background: At present, platinum-doublet chemotherapy or in combination with an immune check point inhibitor are standard treatment for patients with metastatic or recurrent NSCLC which lacks somatic gene alterations. Although CbP is one of the
Autor:
Takehiro Uemura, Osamu Takakuwa, Ken Maeno, Akio Niimi, Kazuki Sone, Yutaka Ito, Tetsuya Oguri, Masaya Takemura, Akira Takeuchi, Satoshi Fukuda, Kensuke Fukumitsu, Yoriko Yamashita, Hirotsugu Ohkubo, Yoshihiro Kanemitsu
Publikováno v:
Anticancer research. 38(9)
Background/aim To investigate whether TTF-1 expression predicts a beneficial response of non-squamous non-small-cell lung cancer (NS-NSCLC) patients to bevacizumab. Patients and methods We retrospectively screened 118 advanced NS-NSCLC patients who w
Autor:
Shuko Morita, Katsuya Hirano, Y. Nakanishi, Isamu Okamoto, Haruko Daga, Yasuo Iwamoto, Atsushi Nakamura, Satoru Miura, Hiroshige Yoshioka, Toshihide Yokoyama, M. Ando, Ryo Ko, Kaoru Tanaka, Ryo Toyozawa, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Akihiro Bessho, T. Ishiguro, Tetsuya Oguri, Motoko Tachihara
Publikováno v:
Journal of Thoracic Oncology. 14:S302
Autor:
Nobuyuki Yamamoto, Yoichi Nakanishi, Katsuya Hirano, Satoru Miura, Kaoru Tanaka, Ryo Toyozawa, Tetsuya Oguri, Atsushi Nakamura, Isamu Okamoto, Takashi Ishiguro, Satoshi Morita, Haruko Daga, Masahiko Ando, Hiroshige Yoshioka, Yasuo Iwamoto, Takuma Yokoyama, Motoko Tachihara, Kazuhiko Nakagawa, Ryo Ko, Akihiro Bessho
Publikováno v:
Journal of Clinical Oncology. 37:e20531-e20531
e20531 Background: Our previous phase 3 study established carboplatin plus the oral fluorinated pyrimidine formulation S-1 as a standard option for first-line treatment of advanced non–small cell lung cancer (NSCLC) (J Clin Oncol 2010; 28:5240). Th
Autor:
Takehiro Uemura, Yutaka Ito, Masaya Takemura, Kazuki Sone, Satoshi Fukuda, Eiji Kunii, Ken Maeno, Yoshihiro Kanemitsu, Hirotsugu Ohkubo, Akio Niimi, Tetsuya Oguri, Osamu Takakuwa
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 102
Objectives In this study, we investigated whether single nucleotide polymorphisms (SNPs) in folylpoly-γ-glutamate synthase (FPGS), which catalyzes the polyglutamation of pemetrexed (PEM), is related to FPGS expression and the response to PEM in non-
Autor:
Yasushiro Fujiwara, Toshiaki Takahashi, Merrill J Egorin, Nobuoki Kohno, Tetsuya Oguri, Terumasa Ohune, Hidetaka Sumiyoshi, Mitsuru Miyazaki
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 1:92-97
To clarify the clinical pharmacological profile of etoposide in the elderly, we carried out prospective therapeutic drug monitoring in 14 patients with advanced lung cancer aged 75 or more years. The patients received 50 mg etoposide as oral capsules